Luc Boblet is a biotech serial entrepreneur with 15 years of experience in therapeutics R&D, technology transfer and business development. Dr. Boblet joined HiFiBiO Therapeutics following its acquisition of H-Immune Therapeutics, an immuno-oncology preclinical stage biotech developing novel immunotherapeutic approaches. As the Co-founder and CEO of H-Immune Therapeutics, he succeeded in launching a novel pipeline through translational collaborations with leading cancer centers in Europe, and by leveraging its unique in vitro immunization-based fully human antibody generation platform (IVI). Prior to H-Immune, Dr. Boblet co-founded and ran Pathoquest, a start-up company spun out of the Institute Pasteur, which develops disruptive unbiased NGS-based diagnostics in the field of infectious diseases. Under his guidance, Pathoquest raised two VC-backed rounds of financing, closed multiple strategic collaborations and corporate partnerships with leading pharma companies (CERBA Laboratories and Covance), and launched several clinicals trials in France and the U.S. From 2011 to 2015, he served on the board of directors of the BioAster Technological Research Institute.
Dr. Boblet holds a biotech engineering degree and a PhD in Molecular Biology/Virology from Université Paris VII.